Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7843059 | 0.95 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| Trifluoromethanesulfonic Acid SCHEMBL29356486 | 0.91 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| SCHEMBL9727370 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TSHRMAPK1GAA | |
| SCHEMBL7419507 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| SCHEMBL29557286 | 0.88 | SIRT1 (0.53) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| SCHEMBL1030124 | 0.86 | PI4KB (0.50) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| SCHEMBL2175797 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| SCHEMBL12368644 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1TSHRMAPK1GAA | |
| Hydrochloric Acid SCHEMBL28584083 | 0.85 | SIRT1 (0.46) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 | |
| SCHEMBL13033265 | 0.84 | SIRT1 (0.49) | SMN1; SMN2ALDH1A1SIRT1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440126-A | Preparation method of mirabegron | 湖南复瑞生物医药技术有限责任公司 | 2020-07-24 | — | — | CN | claimed |
| EP-4313980-B1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC (CA) | 2026-04-22 | — | — | EP | disclosed |
| CN-108368040-B | Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-114531850-B | Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and at least 1 compound selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof | 富士胶片株式会社 | 2024-08-06 | — | — | CN | disclosed |
| CN-117500802-A | LACTIVICIN compounds, their preparation and their use as antibacterial agents | 费多拉制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-111954673-B | New penam derivatives or salts thereof, pharmaceutical compositions and uses thereof | 富士胶片株式会社 | 2023-09-05 | — | — | CN | disclosed |
| CN-110997678-B | Pyrazoloquinazoline derivatives as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-108778273-B | Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections | 默沙东公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114531850-A | Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and 1 or more compounds selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof | 富士胶片株式会社 | 2022-05-24 | — | — | CN | disclosed |
| US-11332485-B2 | Penicillin-binding protein inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-0467647-B1 | Thioalkylthio cephalosporin derivatives | SHIONOGI & CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0594263-A1 | Thioalkylthio cephalosporin derivatives and intermediates | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1994-04-27 | — | — | EP | disclosed |
| US-5214037-A | Antibiotic, bactericide | SHIONOGI & CO., LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| CN-1058595-A | THIOALKYLTHIO CEPHALOSPORIN DERIVATIVES | SHIONOGI & CO (JP) | 1992-02-12 | — | — | CN | disclosed |
| EP-0467647-A2 | Thioalkylthio cephalosporin derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4704457-A | Process for the preparation of (3S)-3-[[[2-(protected amino)-4-thiazolyl]-oxoacetyl]amino]-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0097352-B1 | PROCESS FOR THE PREPARATION OF AZETIDINE SULFONIC ACIDS | E.R. Squibb & Sons, Inc. (US) | 1987-10-07 | — | — | EP | disclosed |
| EP-0097352-A2 | Process for the preparation of azetidine sulfonic acids | E.R. Squibb & Sons, Inc. (US) | 1984-01-04 | — | — | EP | disclosed |
| EP-0092830-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and their application | CIBA-GEIGY AG (CH) | 1983-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332485-B2 | Penicillin-binding protein inhibitors | PEPD, BPGM, EBPL | SMN1; SMN2 3101/4885ALDH1A1 2794/4885SIRT1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.